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Felicetto Ferrara,1 Tiziana Izzo,1 Clelia Criscuolo,1 Cira Riccardi,1 Giada Muccioli,2
Assunta Viola,1 Fabrizio Pane,2 Salvatore Palmieri1Mutations of the nucleophosmin gene (NPM1), in the absence of concurrent FLT3-internal tandemduplication
(FLT3-ITD) have impressive prognostic value in patients with acute myelogenous leukemia (AML), carrying
normal karyotype (NK). In this study we describe treatment results from a series of 19 patients with
NPM1/FLT32 autografted in first complete remission (CR) after conditioning with a regimen, named BuI,
based on high-dose continuous infusion of idarubicin and Busulfan. Ninety-nine consecutive patients (median
age of 54 years)withNKAML autografted in first CRwere analyzed.Nineteen of 99 patients (19%) hadNPM1
mutation in the absence of FLT3 mutations. The control group, accounting for 80 patients, included 16 cases
(15%) with both mutations, 10 (12%) with FLT3/ITD mutation and no NPMmutation, and 54 (68%) in whom
neither NPM1 nor FLT3 mutations were detectable. The median overall survival (OS) for the whole patient
population was 34 months, the median disease-free survival (DFS) was 22 months. Median OS and DFS were
significantly longer for patients with isolatedNPM1mutation as opposed to controls (OS: not reached versus
25 months, P 5 .02; DFS: not reached versus 16 months, P 5 .007, respectively). Of interest, patients with
isolated NPM1 mutation had a better outcome in terms of either OS or DFS compared to the group of 16
NMP11/FLT31 patients. In conclusion, our study suggest that BuI regimen results in favorable clinical out-
come in patients with isolated NPM1mutation, and could be investigated in a randomized study versus other
regimes or repeated courses of high dose cytosine-arabinoside.
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The clinical outcome of acute myelogenous leuke-
mia (AML) is extremely variable, ranging from survival
of a few days to cure [1,2]. Different clinical and
biological features at diagnosis have been reported as
useful for the prediction of clinical outcome [3]; how-
ever, in most AML cases induction therapy must be
initiated as soon as possible; therefore, the possibility1Division of Hematology and Stem cell Transplantation
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into account, with the exception of acute promyelocytic
leukemia, in which morphology, immunophenotype,
and molecular biology allow a rapid diagnosis and the
adoptionof specific therapy [4]. As a consequence, prog-
nostic factors in AMLaremore useful for the prediction
of relapse, rather than for the stratification of induction
therapy [1].Most relevant studies, based on largemulti-
center trials, havedefinitivelydemonstrated that age and
cytogenetic abnormalities at diagnosis are the most
important prognostic determinants for patients with
AML [5-7]. However, nearly half of AML patients
present with normal karyotype (NK) and are classified
as intermediate in the prognostic categorization [6]. In
recent years, new molecular markers have emerged as
significant prognostic parameters; in particular, in pa-
tients with NK, mutations of the nucleophosmin gene
(NPM1), in the absence of concurrent FLT3-internal
tandem duplication (FLT3-ITD) have impressive
prognostic and, beyond prognostication, predictive
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type predicts equivalent favorable outcome after
intensive chemotherapy (CHT) and allogeneic stem
cell transplantation (allo-SCT), whereas in the absence
of this marker clinical outcome was significantly
improved after an allogeneic transplantation [12].
More recently, the favorable impact ofNPM1mutation
has also been reported for AML patients in advanced
age, independently by transplantation procedures in
the postremissionphase [13].Although there is a general
consent that allo-SCT have no role in patients with
NPM1 mutated AML in first complete remission
(CR), no study has specifically focused on the therapeu-
tic results of autologous SCT (ASCT) in NK AML pa-
tients presenting withNPM11/FLT32 genotype [14].
However, the better responsiveness to CHT of
NPM11 patients seems to be, at present, a common
finding observed in evidenceby all clinical trials; accord-
ingly, NPM11 patients could be ideal candidate to
ASCT, given that the ASCT does exert its antileukemic
efficacy by targeting leukemic residual cells after induc-
tion/consolidation CHT by conditioning regimen, in
turn, based on high-dose CHT [15]. Either in older or
in young adult patients with AML, we previously
reported encouraging results in terms of disease-free
survival (DFS) and toxicity of an original conditioning
regimen, called BuI, based on the combination of
high-dose continuous infusions (c.i.) of idarubicin
(IDA) and oral busulphan (Bu). The uniqueness of the
regimen used in our series lies with the specific use of
high dose IDA, in combination with classical dose of
oral Bu and the removal of cyclophoshamide (Cy),
which is not included in induction, consolidation, or
salvage treatment for AML and, therefore, would exert
minimal effect on leukemic population [16,17]. More
recently, we replaced oral with intravenous Bu,
achieving substantial reduction of nonhematologic
toxicity, namely, oralmucositis [18]. In this studywede-
scribe the clinical characteristics and treatment results
from a series of 19 patients with NPM1/FLT32 auto-
grafted in first CR after conditioning with high-dose
continuous infusion IDA and oral or intravenous Bu.PATIENTS AND METHODS
Ninety-nine consecutive patients with normal kar-
yotype AML, treated at our Institutions between April
2003 and June 2009, in which ASCTwas actually given
in first CR, were analyzed. There were 62male patients
(64%) and 37 female patients (36%), with a median age
of 54 years (range: 15-77). Cytogenetic RHG-banding
analysis was performed with a standard method and
the definition of a cytogenetic clone and descriptions
of karyotypes followed the International System for
Human Cytogenetic Nomenclature [19]. A minimum
of 20 bone marrow (BM) metaphases/case wererequired to be examined for a case to be classified as
having NK. Diagnosis was made according to WHO
classification, by using .20% BM blasts as threshold
for the diagnosis of AML [20]. In all cases, diagnosis
was confirmed by immunophenotypic study, as previ-
ously described [21]. Overall 83 patients (84%) were
diagnosed as having de novo AML, whereas in 16
patients (16%) AML arose after a previously diagnosed
myelodysplastic syndrome (MDS).
The analysis of FLT3 mutation was performed as
previously described [22]. Analysis of NPM1mutations
in AML cells was performed by fragment analysis as
previously published [23]. In detail, genomic DNA
was isolated frommononuclear cell preparations stored
at 270C using the DNAzol reagent (GibcoBRL,
Eggenstein, Germany) according to the manufacturer’s
recommendations. Polymerase chain reaction (PCR)
amplification of NPM1 exon 12 was carried out using
primers NPM1-F (50-TTAACTCTCTGGTGGTA
GAATGAA-30) and NPM1-R (50-CAAGACTATT
TGCCATTCCTAAC-30), as follow. The total reac-
tion volume of 50 mL contained approximately 100 ng
DNA, 10 pmol of each primer, deoxynucleoside tri-
phosphates (dNTPs, 10 mM each), 2.5 U Gold Taq
polymerase, and supplied buffer (Applied Biosystems,
Darmstadt, Germany). Samples were amplified using
the following PCR conditions: 95C for 5 minutes; 40
cycles of 94C for 30 seconds; 55C for 1 minute;
72C for 1 minute. PCR products were screened for
the presence of point mutation by Denaturing high-
performance liquid chromatography (D-HPLC).
PCR products were purified by standard methods
and directly sequenced with primer NPM1-R2
(50-GGCATTTT-GGACAACACA-30) using the ABI
Ready Reaction Dye Terminator Cycle Sequencing
Kit (Applied Biosystems).
Patients agedup to60 yearswith denovoAMLwere
given induction treatment consistingof ICE (idarubicin
10mg/sqmon days 1, 3, and 5; cytarabine [ARA-C] 100
mg/sqm as c.i. on days 1-7; etoposide 100 mg/sqm on
days 1-4). Following achievement of CR, patients
were consolidated with the NOVIA regimen (ARA-C
500 mg/sqm every 12 hours on days 1-6 and mitoxan-
trone 10 mg/sqm on days 4-6). Granulocyte colony-
stimulating factor (G-CSF) (10 mg/kg) was added on
day 15 from the start ofNOVIA to inducemobilization
of CD34-positive (CD341) cells. In patients failing to
mobilize after NOVIA (n 5 5, 2 NPM11 and 3 con-
trols), a further attempt was made with 1 cycle of
high-dose ARA-C (3 g/sqm every 12 hours on days 1,
3, and 5). In patients agedover 60 years, induction treat-
ment consisted of continuous sequential infusion of
fludarabine (Flu) and ARA-C as previously reported
[24]. Briefly, Flu was administered at a loading dose of
10 mg/sqm over 15 minutes at day 0 followed by a c.i.
of 20 mg/sqm per 24 hours for 72 hours; ARA-C was
given at a loading dose of 390 mg/sqm (infusion
Table 1. Characteristics of Patients
NPM1+ Controls P-Value
Patients’ number 19 80*
Age, median, (range) 55 (21-72) 52 (15-77) .26
#60 years/>60 years 10/9 (53%/47%) 64/16 (80%/20%) .07
Sex (M/F) 9/10 (47%/53%) 53/27 (66%/34%) .10
de novo/secondary 18/1 (95%/5%) 65/15 (81%/19%) .13
WBC at diagnosis (109/L) 14.8 (2.4-112) 7.3 (1.2-56.4) .003
% BM blasts 80 (30-100) 55 (24-99) .03
% PB blasts 50 (2-90) 75 (5-100) .04
Serum LDH (IU/L) 875 (440-1830) 639 (340-1120) .01
Total numberof CD34+ cells collected (106/kg) 6.5 (3.4-45) 6.8 (2.8-60.1) .12
Oral Bu/i.v.Bu 13/6 (68%/42%) 62/18 (77%/23%) .35
BM indicates bone marrow; PB, peripheral blood;WBC, white blood cell; Bu, Busulfan; LDH, lactate dehydrogenase; AML, acute myelogenous leukemia.
*Sixteen patients had NMP1+/FLT3+ AML; 64 patients had neither NPM1 nor FLT3 mutations.
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1440 mg/sqm per 24 hours for a total of 96 hours.
G-CSF was added on day 15 at a dose of 5 mg/kg. Fol-
lowing CR, patients were given an additional course
reduced by 1 day (c.i. Flu for a total of 48 hours and
c.i. ARA-C for a total of 72 hours) and G-CSF at 10
mg/kg was added at day 15 to shorten neutropenia
andmobilize hematopoietic precursors.The condition-
ing regimen, called I-Bu, consisted of 3 days of c.i. idar-
ubicin (20 mg/sqm from days213 to211) followed by
oral Bu (4mg/kg daily) for 4 days (from days25 to22).
Patients aged over 60 years received the same condi-
tioning regimen reduced by 1 day for either idarubicin
or Bu [17]. In 24 patients, oral Bu was replaced with in-
travenous Bu at a slightly reduced dose (3.2mg/kg daily
fromdays25 to22) as recently published [18]. To pre-
vent seizures, phenytoin (100 mg) was administered
orally beginning 24 h before the first dose of Bu and
continued until 24 h after the last dose. All transfused
blood productsweredepleted of leucocytes tominimize
the risks of alloimmunization and graft-versus-host
disease (GVHD). Infection prophylaxis was based on
oral ciprofloxacin when neutrophils were\1  109/L.
Neither antiviral nor antifungal prophylaxis was per-
formed. Indications for antibiotic therapy included
fever .38C with leukocyte count\1  109/L as well
as signs or symptoms of infection. Intravenous flucona-
zole was used for proven candidiasis infection, whereas
amphotericin B was given for aspergillosis when
suspected (fever persisting for more than 7 days while
on treatment with broad-spectrum antibiotics) orTable 2. Toxicity and Therapeutic Results
N
Median number of months from CR to ASCT (range) 3
Median number of CD34+ cells infused (106/kg) 6.5
Median days to neutrophils recovery to >0.5  109/L 11
Median days to platelet recovery to >20  109/L 18
WHO nonhematologic toxicity episodes 16
Treatment-related mortality
Median DFS (months) not
Median OS (months) not
Relapse post-ASCT 3/19
ASCT indicates autologous stem cell transplantation; CR, complete remissionproven. G-CSF (5 mg/kg) was added for all patients at
day 15 from stem cell infusion. The median number
of CD341 cells collected was 6.7  106/kg (range:
2.8-60.3). The median number of CD341 cells infused
was 6.2 106/kg (range 2.8-24).DFSwas defined as the
time from CR achievement until the month of relapse,
death from any cause, or the date of last follow-up.
Overall survival (OS) was defined as the time fromdiag-
nosis to death or last follow-up. EitherDFS orOSwere
calculated by the Kaplan-Meier method [25]. Differ-
ences between survival curves were evaluated by the
log-rank test. Differences in the distribution of individ-
ual parameters among patient subsets were analyzsed
using the chi-square or theMann-Withney test. All sta-
tistical comparisons used 2-tailed P-value. Multivariate
analysis was performed by a Cox proportional hazard
regressionmodel. The P-value used to define statistical
significance was .05.RESULTS
As indicated in Table 1, overall, 19 of 99 patients
autografted after conditioning with IBu regimen
(19%) had NPM1 mutation in the absence of FLT3
mutations. Three patients with NPM11/FLT32
AML who failed to mobilize CD341 cells and were
consolidated with 3 additional courses of high-dose
ARA-C were excluded from the current analysis. The
control group, accounting for 80 patients, included
16 cases (15%) with both mutations, 10 (12%) patientsPM1+ Controls P-Value
(2-5) 3 (2-6) .87
(3.4-18.4) 6.7 (2.8-23.5) .28
(9-16) 12 (10-18) .24
(15-32) 19 (15-40) .26
(84%) 70 (87%) .36
0 0 n.a.
reached 16 .007
reached 25 .02
(15%) 49/80 (61%) .001
; DFS, disease-free survival; OS, overall survival.
Figure 1. OS and DSF for the whole patient population (median: 34 and 22 months, respectively).
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in whom neither NPM1 nor FLT3mutations were de-
tectable.MedianWBC count (7.3 versus 14.8 109/L,
P5 .003), serumLDH (639 versus 875 IU/L, P5 .01),
percentages of PB (50% versus 75%, P5 .04), and BM
blasts (55% versus 80%, P 5.04) were significantly
higher in the NPM11 patients compared to controls.
Other clinical parameters, including median age and
percentage of patients aged over 60 years, percentage
of secondary AML, and FAB subtype, did not differ
according to the presence or absence ofNPM1 isolated
mutation.However, AMLpost-MDSwas diagnosed in
only 1 patient with NPM11 AML. Finally, percent of
patients receiving intravenous Bu was similar in the 2
groups (P5 .35).
Median time from CR achievement to ASCT was
similar between the 2 groups (3 months, range: 2-5
for NPM11 patients) as opposed to 3 for the control
group (range: 2-6),P5 .87), as shown inTable 2. In ad-
dition, time to neutrophil and platelet recovery to.0.5
 109/L and 20 109/L after ASCT, respectively, was
not different between the group of NPM11 patients
(11 versus 12 days, P 5 .24 for neutrophils; 18 versusFigure 2. OS and DFS of patients with NPM1 isolated mutations as opposed to
isolatedNPM1mutation as opposed to controls (OS: not reached versus 25 mo19 days for platelets, P 5 .35, respectively). Of note,
no difference was recorded as nonhematological
toxicity is concerned. More in detail, the incidence of
oral mucositis, which was the most frequent adverse
effect, occurred in 84% of NPM1 patients and 87%
of controls, P 5 .37. The median number of CD341
cells infused were comparable between the 2 groups
(6.5  106/kg for the NPM11 subgroup, range:
3.4-18.4) as opposed to 6.7 (range: 2.8-23.5) for the
control group, P 5 .28. No case of treatment-related
mortality was recorded either in NPM11 AML
patients or in controls.
After a median follow-up for surviving patients of
36 months (range: 6-93), the median survival for the
whole patient population was 34 months (95% confi-
dence intervals [CIs] 12.1-55.8), whereas the median
DFS was 22 months (95% CIs 8.2-38.2), as shown in
Figure 1. As indicated in Figure 2, median OS and
DFS were significantly longer for patients with
isolated NPM1 mutation as opposed to controls (OS:
not reached versus 25 months, P 5 .02; DFS: not
reached versus 16 months, P 5 .007, respectively).
Of interest, patients with isolated NPM1 mutationcontrols: medianOS and DFS were significantly longer for patients with
nths, P5.02; DFS: not reached versus 16 months, P5.007, respectively).
Figure 3. OS and DFS of patients with NPM1 isolated mutations as opposed to patients with NPM11/FLT31 AML (median OS not reached versus 27
months, P 5 .03; DFS not reached versus 16 months, P 5 .004).
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compared to the group of NMP11/FLT31 patients
(median OS not reached versus 27 months, P 5 .03;
DFS not reached versus 16months, P5 .004) as shown
in Figure 3. Relapse post-ASCT occurred in 3 of 19
patients with NPM1 isolated mutation (16%), 2 with
de novo AML and 1 with AML post-MDS, as opposed
to 49 of 80 in the control group (61%), P5 .001. Over-
all, second CR was achieved in 12 of 52 relapsed
patients (23%) and was almost exclusively limited to
those whose first CR lasted more than 6 months.DISCUSSION
NPM1 gene mutations, which cause aberrant
cytoplasmic expression of nucleophosmin, are the
most frequent genetic alteration in AML, being found
in about 30% cases [26].NPM1mutations are detected
by molecular techniques or surrogates such as immu-
nohistochemistry,Western blotting, and possibly fluo-
rescent activated cell sorter analysis. These methods
are complementary rather than competitive, and offer
a flexible approach to diagnosis; therefore, investiga-
tion of NPM1 mutations is currently considered as
essential for the routine diagnosis of AML [27]. Pa-
tients with NPM1-mutated AML usually respond
well to induction CHT [28], with 75% to 80% achiev-
ing CR. Evidence of the high sensitivity of NPM1-
mutated AML cells to chemotherapy derives from
further clinical observations. In particular, NPM1,
but not FLT3-ITD mutations predict early blast cell
clearance and CR rate in patients with NK-AML or
high-risk MDS [29], after conventional induction
CHT. Moreover, increase sensitivity to chemothera-
peutical agents has also been demonstrated by in vitro
studies, as an effect of interaction between cytoplasmic
NPM and NF-kB in the cytoplasm, resulting in the
sequestration and inactivation of NF-kB [30].In this study we retrospectively analyzed the prog-
nostic relevance of isolatedNPM1mutation in a group
of 99 patients autografted in first CR after condition-
ing with high-dose IDA and Bu. Such a regimen was
specifically designed for AML, by replacing Cy, which
is included in the classical Bu/Cy regimen with IDA
and, in previous studies, provided very encouraging
results in terms of reduction of relapse rate and CR
duration, namely, in patients with intermediate cyto-
genetics [16-18]. In addition, BuI conditioning was
found as able to overcome the adverse prognostic
relevance of FLT3 mutations [31]. Overall, in our
series 35 patients had NPM1 mutation (35%), 16 of
whom are in association with FLT3/ITD mutation.
As previously reported, most NMP11 patients pre-
sented with de novo AML as well as with higher blast
count either in BM or peripheral blood. On the con-
trary, no difference in age, sex, or FAB subtype were
found. Therapeutic results are quite encouraging,
given that after a median follow-up of 35 months
from diagnosis, median OS and DFS have not been
reached, and only 3 of 19 patients (16%) relapsed as
opposed to over 50% in the control group. These
favorable results suggest a peculiar efficacy of the BuI
regimen in this AML patient subset, mainly of IDA,
which was used at high dose as c.i. in the conditioning
regimen. Even though no specific data have been
published, either experimental or clinical evidence
suggests particular sensitivity of NPM11 AML blast
cells to anthracyclines. In anaplastic large cell lym-
phoma, the fusion protein, nucleophosmin-anaplastic
lymphoma kinase (NPM-ALK), results from the
chromosome translocation t(2;5) (p23;q25) and is asso-
ciated with favorable prognosis [32]. A recent study
demonstrated that the downregulation of NPM-ALK
resulted in decreased cell proliferation and increased
cell apoptosis. When used in combination with
chemotherapeutic agents, such as doxorubicin, the
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sitivity of the tumor cells [33]. In young adults with
AML, intensifying induction therapy with a high daily
dose of daunorubicin improved the rate of CR and the
duration of OS compared with the standard dose [34].
Of note, clinical benefit was only observed in patients
with intermediate cytogenetics, in whom most
NPM11 AML cases are found. Similar results were
reported in older AML population, in which benefit
of high-dose daunorubicin was limited to core binding
factor AML as well as to AML with intermediate cyto-
genetics [35]. Taken together, these findings seem to
suggest a peculiar sensitivity of NPM11myelogenous
blasts to CHT, namely, to anthracyclines, and may ac-
count for the favorable results achieved in ourNPM11
AML patient series. In our study, the number of
CD341 cells collected was relatively high (median 6.5
 106/kg for NPM11/FLT32 patients and 6.8 
106/kg in the controls, respectively) and this in previous
studies has been associated with poor prognosis in
AML patients undergoing ASCT or not [36]. How-
ever, this value is lower than 10  106/kg, which was
indicated as cutoff value for the prediction of unfavor-
able outcome [36]. In addition, it is conceivable that in
NPM11/FLT32 AML, patients with less leukemic
cells could have contaminated the graft, given their
peculiar sensitivity to induction and consolidation
chemotherapy.
In conclusion, although the possible benefit of
a conditioning regimen based on high-dose IDA
does clearly need further investigation on a larger
number of patients in a randomized trial, our results
clearly suggest that patients with NPM11/FLT32
AML are ideal candidates for high-dose consolidation
with ASCT.ACKNOWLEDGMENTS
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